Loading clinical trials...
Loading clinical trials...
Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC)
Conditions
Interventions
Cabozantinib
Pembrolizumab
Locations
1
United States
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, United States
Start Date
February 4, 2020
Primary Completion Date
November 25, 2023
Completion Date
May 30, 2026
Last Updated
August 11, 2025
NCT06901531
NCT05677490
NCT07282912
NCT07001748
NCT05753306
NCT06253871
Lead Sponsor
University of California, Irvine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions